Oseltamivir_acid_LCMS_18345_MedChemExpress
奥司他韦杂质标准品列表
奥司他韦杂质——孟成科技（上海）有限公司名称信息结构式奥司他韦杂质Oseltamivir Impurity分子式/Molecular Formula ：C14H22O4分子量/Molecular Weight ：254.33CAS#:1266663-89-1奥司他韦杂质Oseltamivir Impurity 分子式/Molecular Formula ：C14H22O4分子量/Molecular Weight ：254.33CAS#:347378-74-9奥司他韦杂质Oseltamivir Impurity 分子式/Molecular Formula ：C14H22O4分子量/Molecular Weight ：254.33奥司他韦杂质Oseltamivir Impurity 分子式/Molecular Formula ：C14H22O4分子量/Molecular Weight ：254.33CAS#:1234858-94-6奥司他韦杂质Oseltamivir Impurity 分子式/Molecular Formula ：C22H32N2O6分子量/Molecular Weight ：420.51奥司他韦杂质Oseltamivir Impurity 分子式/Molecular Formula ：C22H38N2O9分子量/Molecular Weight ：474.55奥司他韦杂质Oseltamivir Impurity 分子式/Molecular Formula ：C22H36N2O4分子量/Molecular Weight ：392.54奥司他韦杂质Oseltamivir Impurity 分子式/Molecular Formula ：C22H36N2O4分子量/Molecular Weight ：392.54奥司他韦杂质Oseltamivir Impurity 分子式/Molecular Formula ：C26H44N2O4分子量/Molecular Weight ：448.65奥司他韦杂质Oseltamivir Impurity 分子式/Molecular Formula ：C26H44N2O4分子量/Molecular Weight ：448.65奥司他韦杂质Oseltamivir Impurity 分子式/Molecular Formula ：C26H44N2O4分子量/Molecular Weight ：448.65。
Gelucire-14-44-SDS-MedChemExpress
Inhibitors, Agonists, Screening LibrariesSafety Data Sheet Revision Date:Nov.-23-2018Print Date:Nov.-23-20181. PRODUCT AND COMPANY IDENTIFICATION1.1 Product identifierProduct name :Gelucire 14/44Catalog No. :HY-Y1892CAS No. :121548-04-71.2 Relevant identified uses of the substance or mixture and uses advised againstIdentified uses :Laboratory chemicals, manufacture of substances.1.3 Details of the supplier of the safety data sheetCompany:MedChemExpress USATel:609-228-6898Fax:609-228-5909E-mail:sales@1.4 Emergency telephone numberEmergency Phone #:609-228-68982. HAZARDS IDENTIFICATION2.1 Classification of the substance or mixtureNot a hazardous substance or mixture.2.2 GHS Label elements, including precautionary statementsNot a hazardous substance or mixture.2.3 Other hazardsNone.3. COMPOSITION/INFORMATION ON INGREDIENTS3.1 SubstancesSynonyms:NoneFormula:N/AMolecular Weight:N/ACAS No. :121548-04-74. FIRST AID MEASURES4.1 Description of first aid measuresEye contactRemove any contact lenses, locate eye-wash station, and flush eyes immediately with large amounts of water. Separate eyelids with fingers to ensure adequate flushing. Promptly call a physician.Skin contactRinse skin thoroughly with large amounts of water. Remove contaminated clothing and shoes and call a physician.InhalationImmediately relocate self or casualty to fresh air. If breathing is difficult, give cardiopulmonary resuscitation (CPR). Avoid mouth-to-mouth resuscitation.IngestionWash out mouth with water; Do NOT induce vomiting; call a physician.4.2 Most important symptoms and effects, both acute and delayedThe most important known symptoms and effects are described in the labelling (see section 2.2).4.3 Indication of any immediate medical attention and special treatment neededTreat symptomatically.5. FIRE FIGHTING MEASURES5.1 Extinguishing mediaSuitable extinguishing mediaUse water spray, dry chemical, foam, and carbon dioxide fire extinguisher.5.2 Special hazards arising from the substance or mixtureDuring combustion, may emit irritant fumes.5.3 Advice for firefightersWear self-contained breathing apparatus and protective clothing.6. ACCIDENTAL RELEASE MEASURES6.1 Personal precautions, protective equipment and emergency proceduresUse full personal protective equipment. Avoid breathing vapors, mist, dust or gas. Ensure adequate ventilation. Evacuate personnel to safe areas.Refer to protective measures listed in sections 8.6.2 Environmental precautionsTry to prevent further leakage or spillage. Keep the product away from drains or water courses.6.3 Methods and materials for containment and cleaning upAbsorb solutions with finely-powdered liquid-binding material (diatomite, universal binders); Decontaminate surfaces and equipment by scrubbing with alcohol; Dispose of contaminated material according to Section 13.7. HANDLING AND STORAGE7.1 Precautions for safe handlingAvoid inhalation, contact with eyes and skin. Avoid dust and aerosol formation. Use only in areas with appropriate exhaust ventilation.7.2 Conditions for safe storage, including any incompatibilitiesKeep container tightly sealed in cool, well-ventilated area. Keep away from direct sunlight and sources of ignition.Recommended storage temperature:Pure form-20°C 3 years4°C 2 yearsIn solvent-80°C 6 months-20°C 1 monthShipping at room temperature if less than 2 weeks.7.3 Specific end use(s)No data available.8. EXPOSURE CONTROLS/PERSONAL PROTECTION8.1 Control parametersComponents with workplace control parametersThis product contains no substances with occupational exposure limit values.8.2 Exposure controlsEngineering controlsEnsure adequate ventilation. Provide accessible safety shower and eye wash station.Personal protective equipmentEye protection Safety goggles with side-shields.Hand protection Protective gloves.Skin and body protection Impervious clothing.Respiratory protection Suitable respirator.Environmental exposure controls Keep the product away from drains, water courses or the soil. Cleanspillages in a safe way as soon as possible.9. PHYSICAL AND CHEMICAL PROPERTIES9.1 Information on basic physical and chemical propertiesAppearance White to off-white (Oil)Odor No data availableOdor threshold No data availablepH No data availableMelting/freezing point No data availableBoiling point/range No data availableFlash point No data availableEvaporation rate No data availableFlammability (solid, gas)No data availableUpper/lower flammability or explosive limits No data availableVapor pressure No data availableVapor density No data availableRelative density No data availableWater Solubility No data availablePartition coefficient No data availableAuto-ignition temperature No data availableDecomposition temperature No data availableViscosity No data availableExplosive properties No data availableOxidizing properties No data available9.2 Other safety informationNo data available.10. STABILITY AND REACTIVITY10.1 ReactivityNo data available.10.2 Chemical stabilityStable under recommended storage conditions.10.3 Possibility of hazardous reactionsNo data available.10.4 Conditions to avoidNo data available.10.5 Incompatible materialsStrong acids/alkalis, strong oxidising/reducing agents.10.6 Hazardous decomposition productsUnder fire conditions, may decompose and emit toxic fumes.Other decomposition products - no data available.11.TOXICOLOGICAL INFORMATION11.1 Information on toxicological effectsAcute toxicityClassified based on available data. For more details, see section 2Skin corrosion/irritationClassified based on available data. For more details, see section 2Serious eye damage/irritationClassified based on available data. For more details, see section 2Respiratory or skin sensitizationClassified based on available data. For more details, see section 2Germ cell mutagenicityClassified based on available data. For more details, see section 2CarcinogenicityIARC: No component of this product present at a level equal to or greater than 0.1% is identified as probable, possible or confirmed human carcinogen by IARC.ACGIH: No component of this product present at a level equal to or greater than 0.1% is identified as a potential or confirmed carcinogen by ACGIH.NTP: No component of this product present at a level equal to or greater than 0.1% is identified as a anticipated or confirmed carcinogen by NTP.OSHA: No component of this product present at a level equal to or greater than 0.1% is identified as a potential or confirmed carcinogen by OSHA.Reproductive toxicityClassified based on available data. For more details, see section 2Specific target organ toxicity - single exposureClassified based on available data. For more details, see section 2Specific target organ toxicity - repeated exposureClassified based on available data. For more details, see section 2Aspiration hazardClassified based on available data. For more details, see section 212. ECOLOGICAL INFORMATION12.1 ToxicityNo data available.12.2 Persistence and degradabilityNo data available.12.3 Bioaccumlative potentialNo data available.12.4 Mobility in soilNo data available.12.5 Results of PBT and vPvB assessmentPBT/vPvB assessment unavailable as chemical safety assessment not required or not conducted.12.6 Other adverse effectsNo data available.13. DISPOSAL CONSIDERATIONS13.1 Waste treatment methodsProductDispose substance in accordance with prevailing country, federal, state and local regulations.Contaminated packagingConduct recycling or disposal in accordance with prevailing country, federal, state and local regulations.14. TRANSPORT INFORMATIONDOT (US)This substance is considered to be non-hazardous for transport.IMDGThis substance is considered to be non-hazardous for transport.IATAThis substance is considered to be non-hazardous for transport.15. REGULATORY INFORMATIONSARA 302 Components:No chemicals in this material are subject to the reporting requirements of SARA Title III, Section 302.SARA 313 Components:This material does not contain any chemical components with known CAS numbers that exceed the threshold (De Minimis) reporting levels established by SARA Title III, Section 313.SARA 311/312 Hazards:No SARA Hazards.Massachusetts Right To Know Components:No components are subject to the Massachusetts Right to Know Act.Pennsylvania Right To Know Components:No components are subject to the Pennsylvania Right to Know Act.New Jersey Right To Know Components:No components are subject to the New Jersey Right to Know Act.California Prop. 65 Components:This product does not contain any chemicals known to State of California to cause cancer, birth defects, or anyother reproductive harm.16. OTHER INFORMATIONCopyright 2018 MedChemExpress. The above information is correct to the best of our present knowledge but does not purport to be all inclusive and should be used only as a guide. The product is for research use only and for experienced personnel. It must only be handled by suitably qualified experienced scientists in appropriately equipped and authorized facilities. The burden of safe use of this material rests entirely with the user. MedChemExpress disclaims all liability for any damage resulting from handling or from contact with this product.Caution: Product has not been fully validated for medical applications. For research use only.Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA。
奥拉西坦工厂工艺
奥拉西坦英文名称 Oxiracetam 中文化学名称4-羟基-2-氧代-1-吡咯烷乙酰胺 英文化学名称4-Hydroxy-2-oxo-pyrrolidineacetamide 结构式NCH 2CONH 2HOO化学式 C 6H 10N 2O 3 分子量 158.16 理化性质本品为白色结晶或结晶性粉末，无臭，味微甜。
在水中易溶，在甲醇或乙醇中极微溶解，在丙酮、氯仿或苯中几乎不溶。
熔点为166~169℃。
本品为吡拉西坦的类似物，可改善老年性痴呆和记忆障碍症患者的记忆和学习功能。
研究结果提示，本品可促进磷酰胆碱和磷酰乙醇胺合成，提高大脑中ATP/ADP 的比值，使大脑中蛋白质和核酸的合成增加。
用于脑损伤及引起的神经功能缺失、记忆与智能障碍的治疗。
化学反应过程.4-氯-3-羟基丁酸乙酯与甘氨酰胺盐酸盐反应得到奥拉西坦。
CloOHO+NH 2NH 2O.HClNa 2CO 3/C 2H 5OH4-氯-3-羟基丁酸乙酯NCH 2CONH 2HOO甘氨酰胺盐酸盐工艺流程图生产区域划分及工艺流程方框图工艺图合 成过滤、浓 缩溶解、萃取无水乙醇/碳酸钠水溶液碳酸钠减压顶蒸、溶解、离心、洗涤、干燥溶解纯化水/活性炭浓缩、过滤回收乙醇纯化水/二氯甲烷回收二氯甲烷甲醇 回收甲醇奥拉西坦粗品甲醇结 晶人员 一次更衣二次更衣甘氨酰胺盐酸4-氯-3-羟基丁酸乙酯检验 合格工艺过程及工艺条件 奥拉西坦粗品的制备 工艺配比（重量比） 物料名称 甘氨酰胺盐酸盐 4-氯-3-羟基丁酸乙酯无水 乙醇 碳酸钠 二氯甲烷 甲醇 投料量 1.0 1.557.15+1.44+1.440.959.71.44+0.36工艺过程及工艺条件在R0104B 反应罐中加入7.15倍无水乙醇（重量比，以甘氨酰胺盐酸盐计；下同），搅拌条件下加入甘氨酰胺盐酸盐和碳酸钠，室温条件(20~25℃)下搅拌1小时。
然后加入1.55倍4-氯-3-羟基丁酸乙酯；加毕慢慢升温至回流，并保温回流反应24小时。
茶多酚对人脂肪来源间充质干细胞成骨分化的影响
茶多酚对人脂肪来源间充质干细胞成骨分化的影响王华1，齐玉成-杨云芳-赵艺洋2,王慧1，陈培1，杨旭芳1(1.牡丹江医学院，黑龙江牡丹江157011；2.南方医科大学第一临床医学院，广东广州510515)摘要：目的探讨茶多酚(Epigallocatechin-3-gallate,EGCG)对人脂肪间充质干细胞(human adipose-derived mesenchy^-mal stem cells,hADSCs)成骨分化的影响。
方法利用胶原酶消化法和贴壁筛选法从人脂肪组织中分离、培养及扩增hADSCs,倒置显微镜下观察各代hADSCs的形态学特点;利用流式细胞术检测各代hADSCs免疫学表型;取P3代细胞进行成骨诱导分化，实验分三组，即未诱导组、常规成骨诱导组与EGCG组(常规成骨诱导+5^mol/L EGCG),14d后，镜下观察细胞形态学改变及碱性磷酸酶(ALP)染色。
结果体外分离、培养的hADSCs形态均一;流式细胞术结果显示hADSCs具备间充质干细胞的免疫学表型，即CD44、CD73、CD105阳性;成骨诱导14d后部分细胞由长梭形变成多角形，细胞呈现聚集趋势；ALP染色显示EGCG组呈强阳性。
结论成功的从脂肪组织中分离培养出了hADSCs,EGCG能加强其成骨分化能力，这将为骨质疏松症的临床药物开发提供新的思路，亦为组织工程骨的构建提供丰富可靠的种子细胞来源。
关键词：EGCG；人脂肪来源间充质干细胞;成骨分化中图分类号：R595.2文献标识码：A文章编号：1001-7550(2021)01-0001-04Effect of EGCG on osteogenic differentiation of human adipose-derived mesenchymal stem cellsWANG Hua et al(Mudanjiang Medical University,Mudanjiang157011,China)Abstract:Objective To explore the effect of tea polyphenol EGCG on the osteogenic differentiation of human adipose-derived mesenchymal stem cells(hADSCs) .Methods To isolate,culture and amplify hADSCs from human adipose tissue by collagenase digestion and adherent screening methods, the morphological characteristics of each passage of hADSCs were observed under an inverted microscope.The immunophenotype of each generation of hADSCs was detected by flow-cytometry.P3passage cells were taken for osteogenic induction and differentiation,and were divided into three groups:non-induced group, conventional osteogenic induction group and EGCG group(conventional osteogenic induction with+5Rmol/L EGCG).After14days,morphological changes and alkaline phosphatase(ALP)staining were observed under the microscope.Results The morphology of hADSCs isolated and cultured in vitro was uni-form.The results of flow cytometry showed that hADSCs had the immunophenotype of mesenchymal stem cells,such as CD44,CD73and CD105.After14days of osteogenic induction,some cells changed from long spindle shape to polygonal shape,and the cells showed aggregation trend.ALP staining showed strong positive in EGCG group.Conclusion hADSCs have been successfully isolated and cultured from adipose tissue.EGCG can enhance the osteogenic differentiation ability of hADSCs,which will provide a new idea for the clinical drug development of osteoporosis and provide an abundant and reliable source of seed cells for the construction of tissue-engineered bone.Key words:EGCG;human adipose-derived mesenchymal stem cells；osteogenic differentiation随着人口老龄化,骨质疏松症已成为影响人们生活质量的主要因素之一⑷。
抗体公司
赛信通（上海）生物试剂有限公司
上海市浦东南路1101号远东大厦514室，200120 info@cst www.cst 2158356288 公司总部: 美国
Established in Beverly, MA in 1999, Cell Signaling Technology (CST) is a privatelyowned company with over 400 employees worldwide. We are dedicated to providing innovative research tools that are used to help define mechanisms underlying cell function and disease. Since its inception, CST has become the world leader in the production of the highest quality activationstate and total protein antibodies utilized to expand knowledge of cell signaling pathways. Our mission is to deliver the world's highest quality research tools that accelerate progress in biological research and personalized medicine. 总引用数为4670，来自于1966篇文章。最常引用的试剂包括： Akt, ERK2, ERK1, p38, Akt1。
AbD Serotec (BioRad)
桑迪亚医药技术上海有限责任公司
桑迪亚医药技术(上海)有限责任公司桑迪亚医药技术（上海）有限责任公司（Sundia MediTech Company, Ltd.）是一家外商独资企业，注册资本5000万元人民币，于2004年6月8日正式运营。
主营业务包括CRO及新药研发。
公司的管理人员，从CEO到各部门主管，全都来自国内外各专业领域内的一流专家，包括合成化学、药物化学、药物设计、药代动力学、企业管理等。
公司位于浦东张江高科技园区，拥有一个占地面积约5000平方米的科研中心，装备了世界一流的科研仪器，包括液相色谱-质谱联用仪（Agilent 1100 LC-Finnigan MSD）、制备型高效液相色谱仪（Gilson）、微波合成仪等成套先进设备，并自购了联机化学文献库检索（Crossfire），化学和生物信息数据管理系统CBIS软件（ChemInnovation, USA），为公司的科研发展提供了强大的硬件和软件保证。
1.Analytical Development ScientistInformation on the job holder:Required experience:Information on the job:Work contacts:2.Scientist in Formulation Information on the job holder:Required experience:Information on the job:Work contacts:3.生物部实习生Information on the job holder:Required experience:Work contacts:4.Analytical Manager Information on the job holder:Required experience:Information on the job:Work contacts:5.Scientist in Preormulation Information on the job holder:Required experience:Information on the job:Work contacts:6.生物信息学研究员Information on the job holder:Required experience:Information on the job:Work contacts:7.Bioanalytical Scientist Information on the job holder:Required experience:Information on the job:Work contacts:8.Seperation Scientist Information on the job holder:Required experience:Information on the job:Work contacts:9.新药临床前开发管理Information on the job holder:Required experience:Information on the job:Work contacts:。
生物碱类植物化学物治疗和预防阿尔茨海默病的研究进展
生物碱类植物化学物治疗和预防阿尔茨海默病的研究进展李宝龙;单毓娟;刘旭;贾博宇;周忠光【摘要】Alzheimer disease (AD) is the most common type of senile dementia, a neurodegenerative disease without effective therapeutic drugs. At present, some phytochemicals with excellent bioactivities in preventing and treating AD have been targeted in the field of new drugs exploitation. This review summarizes the related literatures published recently which mainly show the latest and resegrch progress of a variety of alkaloids such as galanthamine, physostigmine, huperzine, vinca -derived alkaloids, nicotine in the prevention and therapy for AD.%阿尔茨海默病(AD)是最常见的老年痴呆型神经退行性疾病,目前尚无特效药.研究与开发防治阿尔茨海默病的有效植物化学物是当今医药学研究领域的重要课题之一.通过对近年来有代表性的文献进行分析归纳,总结了加兰他敏、毒扁豆碱、石杉碱、长春花属以及烟碱等生物碱类植物化学物治疗和预防阿尔茨海默病的研究进展.【期刊名称】《中医药学报》【年(卷),期】2012(040)003【总页数】3页(P145-147)【关键词】阿尔茨海默病;植物化学物;生物碱【作者】李宝龙;单毓娟;刘旭;贾博宇;周忠光【作者单位】黑龙江中医药大学,黑龙江哈尔滨 150040;哈尔滨工业大学,黑龙江哈尔滨 150090;黑龙江中医药大学,黑龙江哈尔滨 150040;黑龙江中医药大学,黑龙江哈尔滨 150040;黑龙江中医药大学,黑龙江哈尔滨 150040【正文语种】中文【中图分类】R741.05植物化学物(phytochemicals)是植物中存在一类生物活性成分，由种类繁多的化学物质组成。
肝病专业英语词汇
3α-羟类固醇脱氢酶(Y' 蛋白) γ -谷氨酰转移酶 γ-氨基丁酸 甲胎蛋白 人兽共患病 异种肝移植 脂肪性纤维瘤,黄色瘤 黄嘌呤氧化酶 黄斑瘤 全球移植中心名录 窗口期 肝豆状核变性 肥达反应 外斐反应 韦克斯勒成人智力测验 呕吐 视觉诱发电位 病毒学应答 病毒复制 病毒性肝炎 静脉-静脉转流 VOD 肝小静脉闭塞病 静脉-动脉转流 血管活性肽 静脉曲张 胆管消失综合征 疫苗 熊去氧胆酸 尿胆素原 尿胆素 二磷酸尿苷异构酶 尿素生成 鸟氨酸循环,尿素循环 上消化道出血 粗纤维调节素 肝未分化肉瘤 充盈不足学说 非结合高胆红素血症 游离胆红素,非结合胆红素 超声(波)检查法
短潜伏期肝炎 移动性浊音 腹水白蛋白浓度梯度 血清肝炎 血清诊断 血清胆红素 血清白蛋白 血清学应答 乙肝血清学检查 血清转换 败血症相关胆汁淤积 正链,有义链 镇静剂 次级胆酸 海蓝组织细胞增多症 硬化疗法 硬化性胆管炎 日本血吸虫病 湄公血吸虫 曼氏血吸虫 日本血吸虫 间插血吸虫 埃及血吸虫 血吸虫 瘢痕形成期 粗面内质网 滚环机制(环状DNA复制的机理) RNA干扰 核酶 核糖体 胆固醇逆向转运
伤寒 Ⅳ型胶原 Ⅲ型前胶原 甲肝和乙肝疫苗 抑癌基因 肿瘤坏死因子 肝结核 滋养体 甘油三酯 颠换效应 经颈静脉肝内门腔分流 转换 输血传染的病毒 输血性肝炎 转化生长因子
transcatheter arterial chemoembolization 肝动脉化疗栓塞 trans-activation toxic hepatitis total cholesterin total bilirubin tomor necrosis factor tocopherol TNF-related apoptosis inducing ligand tissue inhibitor of metalloproteinase thymosin Thymopolypeptides for Injection thromboxane the core promoter element tentative diagnosis tension of muscle tenderness Telbivudine taurocholic acid taurochenodeoxycholate acid systemic inflammatory response syndrome syncytial giant-cell hepatitis sustained virus response sustained response 反式激活 中毒性肝炎 总胆固醇 总胆红素 肿瘤坏死因子 生育酚,维生素E 肿瘤坏死因子相关凋亡诱导配体 基质金属蛋白酶组织抑制物 胸腺肽 胸腺肽 血栓素 核心启动子元件,启动子核心元件 暂时的(假定的)诊断,试验性诊断 肌张力 压痛 LdT 牛(磺)胆酸 牛磺鹅(去氧)胆酸盐,牛磺鹅(脱氧)胆酸盐 全身炎症反应综合症 融合巨细胞性肝炎 持续病毒应答 持久应答